Chief Medical Officer, Executive VP Clinical Development
Kronos Bio
San Mateo, California, United States
Jorge DiMartino is Chief Medical Officer and Executive Vice President of Clinical Development at Kronos Bio, a biotech company focused on drugging transcriptional dysregulation in cancer. Jorge trained in pediatrics and pediatric hematology/oncology at Stanford University School of Medicine. After starting his career as an academic physician scientist at Stanford and Cincinnati Children’s Hospital, Jorge moved to Industry as one of the founding members of the Exploratory Clinical Development group at Genentech. In this role, Jorge played a key role in the early development of the hedgehog pathway inhibitor vismodegib and the BCL-2 inhibitors, navitoclax and venetoclax. Jorge left Genentech to lead the epigenetics research efforts at Celgene. In collaboration with corporate partners Agios and Epizyme, he contributed to the design and analysis of early clinical studies of the IDH2 inhibitor enasidenib and the DOT1L inhibitor pinometostat. As Vice President of Translational Development, Jorge co-led the Protein Homeostasis and Epigenetics Thematic Center of Excellence, a vertically integrated research unit spanning drug discovery through clinical Proof of Concept. Jorge joined Kronos Bio in December of 2019 and has built the company’s clinical and translational development capabilities while leading the development of its 2 clinical stage assets, KB-0742 and lanraplenib.
Disclosure information not submitted.
Thursday, November 2, 2023
4:00 PM – 5:30 PM
